New products from Zytovision
The FlexISH RET/KIF5B TriCheck™ Probe (Prod. No. Z-2269-50/-200)
is designed to detect inversions involving the chromosomal region 10q11.21 harboring the RET gene and the chromosomal region 10p11.22 harboring the KIF5B gene. Using this probe, it is possible to discriminate between KIF5B-RET inversions and RET translocations involving fusion partners other than KIF5B. RET rearrangements are found in non-small cell lung cancer (NSCLC) with an incidence of 1-2%. The result of the pericentric inversion of chromosome 10 [inv(10)(p11.2q11.2)] is a homo-dimerization of the coiled-coil domains of KIF5B and causes an aberrant activation of the receptor tyrosine kinase of RET, a mechanism known from KIF5B-ALK fusion which is also found in non-small cell lung adenocarcinoma (LADC).
The ZytoLight SPEC SPI1 Dual Color Break Apart Probe (Prod. No. Z-2291-50)
is designed to detect rearrangements involving the chromosomal region 11p11.2 harboring the Spi-1 proto-oncogene (SPI1) gene. SPI1 rearrangements were detected in some pediatric T-cell acute lymphoblastic leukemia (T-ALL) cases resulting in the fusion of the N-terminal region of the fusion partner to the C-terminal DNA binding ETS domain of the SPI1 protein. SPI1 fusion positive cases show markedly elevated SPI1 expression. T-ALL patients with SPI1 fusion show a uniformly poor overall survival and seem to be incurable with current standard chemotherapy.
The ZytoDot 2C Glioma 1p/19p Probe Set (Prod. No. C-3076-10/-40)
is designed to detect deletions affecting the short arm of chromosome 1 (1p36.31) and the long arm of chromosome 19 (19q13) which are frequently found in human gliomas and neuroblastomas. Loss of 1p is a strong prognostic factor in patients with neuroblastoma. Loss of 1p reliably identifies patients at high risk in stages I, II, and IVS, which otherwise are clinically favorable. Several studies showed correlation of combined allelic losses at 1p36 and 19q13 with oligodendroglioma histology and association with both chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
